161 related articles for article (PubMed ID: 25699651)
1. Decitabine treatment could ameliorate primary iron-overload in myelodysplastic syndrome patients.
Shucheng G; Chunkang C; Youshan Z; Juan G; Chengming F; Xi Z; Chao X; Xiao L
Cancer Invest; 2015 Apr; 33(4):98-106. PubMed ID: 25699651
[TBL] [Abstract][Full Text] [Related]
2. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of hypermethylation of DLC-1 gene in myelodysplastic syndrome patients and effects of decitabine on DLC-1 gene expression].
Fu HY; Zhou HR; Yan JG; Chen CJ; Shen JZ
Zhonghua Yi Xue Za Zhi; 2017 Feb; 97(6):412-417. PubMed ID: 28219126
[No Abstract] [Full Text] [Related]
4. [Methylation of FHIT gene promoter region in DNA from plasma of patients with myelodysplastic syndromes and demethylating effect of decitabine].
Deng YF; Zhang L; Zhang XQ; Hu MQ; Dai D; Zhang XZ; Xu YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1144-8. PubMed ID: 23114136
[TBL] [Abstract][Full Text] [Related]
5. [Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature].
Gao Y; Ping B; Zhou S
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Feb; 32(2):280-2. PubMed ID: 22381778
[TBL] [Abstract][Full Text] [Related]
6. Decitabine in myelodysplastic syndromes.
Saba HI; Wijermans PW
Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
[TBL] [Abstract][Full Text] [Related]
7. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Borthakur G; Ahdab SE; Ravandi F; Faderl S; Ferrajoli A; Newman B; Issa JP; Kantarjian H
Leuk Lymphoma; 2008 Apr; 49(4):690-5. PubMed ID: 18398735
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
9. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.
Wu L; Shi W; Li X; Chang C; Xu F; He Q; Wu D; Su J; Zhou L; Song L; Xiao C; Zhang Z
J Transl Med; 2016 Mar; 14():66. PubMed ID: 26944860
[TBL] [Abstract][Full Text] [Related]
10. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
Tohyama K
Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
[TBL] [Abstract][Full Text] [Related]
11. The Relationship of Serum Hemojuvelin and Hepcidin Levels with Iron Overload in Nonalcoholic Fatty Liver Disease.
Boga S; Alkim H; Alkim C; Koksal AR; Bayram M; Yilmaz Ozguven MB; Tekin Neijmann S
J Gastrointestin Liver Dis; 2015 Sep; 24(3):293-300. PubMed ID: 26405701
[TBL] [Abstract][Full Text] [Related]
12. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
Sekeres MA
Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Lübbert M
Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
[No Abstract] [Full Text] [Related]
14. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Yee KW; Jabbour E; Kantarjian HM; Giles FJ
Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
17. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
18. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A
Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386
[TBL] [Abstract][Full Text] [Related]
19. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
Qin T; Castoro R; El Ahdab S; Jelinek J; Wang X; Si J; Shu J; He R; Zhang N; Chung W; Kantarjian HM; Issa JP
PLoS One; 2011; 6(8):e23372. PubMed ID: 21858090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
